AngeloSambunarisMD

Psychiatry • Alpharetta, GA

Medical Director at Dr. Sambunaris & Associates

Join to view full profile

Dr. Sambunaris is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Sambunaris' full profile

Already have an account?

Office
5755 North Point Parkway
Suite 256
Alpharetta, GA 30022
Phone+1 770-817-9200

Fax+1 770-817-9201
Is this information wrong?

Education & Training

National Institutes of Health Clinical CenterResidency, Psychiatry, 1991 - 1993
University of ColoradoResidency, Psychiatry, 1989 - 1991
Penn State Milton S Hershey Medical CenterInternship, Internal Medicine, 1987 - 1988
University of Colorado School of Medicine Anschutz Medical CampusClass of 1987

Certifications & Licensure

GA State Medical License 1998 - 2025
CO State Medical License 1989 - 2017
CT State Medical License 1995 - 1998

Clinical Trials

Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression Start of enrollment: 2010 Nov 01
Completed
Phase 2
Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD) Start of enrollment: 2013 Oct 01
Completed
Phase 2
Genomics Used to Improve DEpression Decisions Start of enrollment: 2014 Apr 01
Completed
Not Applicable

Publications & Presentations

PubMed

In Memoriam Donald S. Robinson, MD.
William Z Potter, Angelo Sambunaris, Steven M Paul> ;Neuropsychopharmacology. 2023 Jan 1
8 citations
Effects of levomilnacipran extended-release on major depressive disorder patients with cognitive impairments: post-hoc analysis of a phase III study.
Keith Wesnes, Carl Gommoll, Changzheng Chen, Angelo Sambunaris, Roger S. McIntyre, Philip D. Harvey> ;International Clinical Psychopharmacology. 2017 Mar 1
13 citations
Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multi...
Cynthia Richards, Roger S. McIntyre, Richard H. Weisler, Angelo Sambunaris, Olga Brawman-Mintzer, Joseph Gao, Brooke Geibel, Matthew Dauphin, Manisha Madhoo> ;Journal of Affective Disorders. 2016 Dec 1
11 citations
Effects of levomilnacipran extended-release on motivation/energy and functioning in adults with major depressive disorder.
Michael E. Thase, Carl Gommoll, Changzheng Chen, Kenneth Kramer, Angelo Sambunaris> ;International Clinical Psychopharmacology. 2016 Nov 1
17 citations
Vilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose study
Carl Gommoll, Giovanna Forero, Maju Mathews, Rene Nunez, Xiongwen Tang, Suresh Durgam, Angelo Sambunaris> ;International Clinical Psychopharmacology. 2015 Nov 1
19 citations
Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placeb...
Angelo Sambunaris, Carl Gommoll, Changzheng Chen, William M. Greenberg> ;International Clinical Psychopharmacology. 2014 Jul 1
49 citations
Lisdexamfetamine Dimesylate Augmentation in Adults With Persistent Executive Dysfunction After Partial or Full Remission of Major Depressive Disorder
Manisha Madhoo, Richard S.E. Keefe, Robert M. Roth, Angelo Sambunaris, James Wu, Madhukar H. Trivedi, Colleen Anderson, Robert Lasser> ;Neuropsychopharmacology. 2014 May 1
16 citations
Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression
Arif Khan, Angelo Sambunaris, John Edwards, Adam Ruth, Donald S. Robinson> ;International Clinical Psychopharmacology. 2014 Mar 1
69 citations
A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder.
Angelo Sambunaris, Anjana Bose, Carl Gommoll, Changzheng Chen, William M. Greenberg, David V. Sheehan> ;Journal of Clinical Psychopharmacology. 2014 Feb 1
37 citations
A Randomized Controlled Trial of the Efficacy and Safety of Lisdexamfetamine Dimesylate as Augmentation Therapy in Adults With Residual Symptoms of Major Depressive Di...
Madhukar H. Trivedi, Andrew J. Cutler, Cynthia Richards, Robert Lasser, Brooke Geibel, Joseph Gao, Angelo Sambunaris, Ashwin A. Patkar> ;The Journal of Clinical Psychiatry. 2013 Aug 15
6 citations
Clinical evaluation of the Daily Assessment of Symptoms-Anxiety (DAS-A): a new instrument to assess the onset of symptomatic improvement in generalized anxiety disorder.
Douglas Feltner, J. Harness, Jerri Brock, Angelo Sambunaris, Joseph C. Cappelleri, Robert Morlock> ;CNS Neuroscience & Therapeutics. 2009 Mar 1
111 citations
Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.
Andrew A. Nierenberg, John H. Greist, Craig H. Mallinckrodt, Apurva Prakash, Angelo Sambunaris, Gary D. Tollefson, Madelaine M. Wohlreich> ;Current Medical Research and Opinion. 2007 Jan 23
30 citations
Development of new antidepressants.
Angelo Sambunaris, Jan M Keppel Hesselink, Roger Pinder, John Panagides, Stephen M. Stahl> ;The Journal of Clinical Psychiatry. 1997 May 1
7 citations
Stroke-related aphasias mistaken for psychotic speech: two case reports.
Angelo Sambunaris, Thomas M. Hyde> ;Journal of Geriatric Psychiatry and Neurology. 1994 Jul 1
Join now to see all

Professional Memberships

American Psychiatric Association - APA
Member